Close
Clinical Pharmacogenetics Implementation Consortium

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

CPIC Co-Principal Investigators
Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Teri E. Klein, Ph.D.
Stanford University

Co-Investigator
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Teri E. Klein, Ph.D.
Stanford University

Kelly E. Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital

Michelle Whirl-Carrillo, Ph.D.
Stanford University

Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital

Dan M. Roden, M.D.
Vanderbilt University

Rachel F. Tyndale, Ph.D.
University of Toronto and CAMH

Larisa Cavallari, Pharm.D.
University of Florida

Stuart A. Scott, Ph.D.
Stanford Univerisity and Stanford Healthcare

Sara Van Driest, M.D., Ph.D.
Vanderbilt University

Scientific Advisory Board

Julie A. Johnson, Pharm.D.
University of Florida

Gwendolyn A. McMillin, Ph.D.
ARUP Laboratories

Robert Nussbaum, M.D.
University of California, San Francisco

Heidi Rehm, Ph.D.
Partners Healthcare

Marc S. Williams, M.D.
Geisinger

Sandy Aronson
Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D.
Northwestern University

Houda Hachad, Pharm.D., M. Res.
AccessDx/Medtek21

Andrea Gaedigk, Ph.D.
Children’s Mercy



  • Response to the American Academy of Pediatrics' Statement "Eliminating Race-Based Medicine" May 16, 2022
    On May 2nd, the American Academy of Pediatrics (AAP) released a pre-published policy statement titled “Eliminating Race-Based Medicine,” noting that race is a “historically derived social construct that has no place as a biologic proxy.” The statement provides necessary and meaningful commentary on “the medical field’s history of inaccurate applications of race correction and adjustment […]
  • National Academy Seeking Public Feedback on Use of Population Descriptors in Genomics Research March 21, 2022
     The National Academy's Committee on Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research is now actively requesting public comments from those involved in genomics research about how they use descriptors like race, ethnicity, and ancestry as well as thoughts on potential improvements to usage. For those who would like to be considered […]
  • Update to individual statin pathways to support release of new CPIC guidelines for statins February 21, 2022
    To coincide with the release of the updated CPIC guidelines for SLCO1B1, ABCG2 and CYP2C9 and statin-associated musculoskeletal symptoms, we have updated the statin pharmacokinetic (PK) pathways. We now have one PK pathway for each individual drug in the guideline and have added details of the specific metabolites as well as the candidate genes and […]
  • CPIC Publishes Guideline for SLCO1B1, ABCG2, CYP2C9 and Statin Therapy February 19, 2022
    The CPIC guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms (SAMS) has been published in the journal Clinical Pharmacology and Therapeutics. This guideline is an update to the CPIC guideline for simvastatin and SLCO1B1, but now includes expanded literature review on four additional genes, ABCG2, CYP2C9, HMGCR and CYP3A4/5 and all statins. The guideline […]
  • Registration opens for CPIC-PGRN 2022 meeting in Denver, Colorado February 14, 2022
    We are excited to announce that registration is open for the 2022 CPIC-PGRN meeting: Diversifying PGx Science to Improve Implementation. The meeting will be held at the University of Colorado on May 10th, 11th, and 12th in Denver, CO. Registration, agenda, and hotel information available at the meeting website. Early bird registration is now open and is $250.00.  […]